Synergistic Effect of Bypassing Agents and Sequence Identical Analogue of Emicizumab and Fibrin Clot Structure in the In Vitro Model of Hemophilia A

Development of inhibitors to factor VIII (FVIII) occurs in approximately 30% of severe hemophilia A (HA) patients. These patients are treated with bypassing agents (activated prothrombin complex concentrate [aPCC] and recombinant activated FVII-rFVIIa). Recently, a bispecific FIX/FIXa- and FX/FXa-di...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:TH Open
Huvudupphovsmän: Zong, Yanan, Antovic, Aleksandra, Soutari, Nida Mahmoud Hourani, Antovic, Jovan, Pruner, Iva
Materialtyp: Artigo
Språk:Inglês
Publicerad: Georg Thieme Verlag KG 2020
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7373667/
https://ncbi.nlm.nih.gov/pubmed/32704613
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1055/s-0040-1710032
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk